NCT02518945 trial results

Inclusion Criteria: * Patients with type 1 diabetes mellitus: Fasting c-peptide \< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis and treatment with liraglutide at maximal tolerated doses for at least 6 months prior to start of the study. * Willing to use a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily * HbA1c of less than or equal to 11%. * Well versed with carbohydrate counting * Age 18-75 years Exclusion Criteria: * Type 1 diabetes for less than 12 months. * Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks * Hepatic disease (transaminase \> 3 times normal) or cirrhosis * ESRD on hemodialysis; and or e-GFR less than 30 ml/min/1.73m2 * HIV or Hepatitis C positive status * Participation in any other concurrent clinical trial * Any other life-threatening, non-cardiac disease * Use of an investigational agent or therapeutic regimen within 30 days of study * History of pancreatitis * Pregnancy * Inability to give informed consent * History of gastroparesis * History of medullary thyroid carcinoma or MEN 2 syndrome * Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer * Women of childbearing potential who are not using adequate contraception * Women who are pregnant * History of serious hypersensitivity reaction to these agents.